Anna Paruzynski

BioNTech (Germany) — Germany

Biochemistry, Genetics and Molecular Biology · Life Sciences

14h-index4.0kcitations36works73.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(19), CRISPR and Genetic Engineering(14), CAR-T cell therapy research(9), Immunotherapy and Immune Responses(8), RNA Interference and Gene Delivery(6)

Publications36 total

Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Nature Medicine·2025· 73 citedOpen Access
The balance between the intronic miR-342 and its host gene Evl determines hematopoietic cell fate decision
Leukemia·2021· 14 citedOpen Access
Mapping Active Gene-Regulatory Regions in Human Repopulating Long-Term HSCs
Cell stem cell·2018· 14 citedOpen Access
IVAC MUTANOME: A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma
Annals of Oncology·2017· 14 citedOpen Access
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Nature·2017· 2.4k cited
Abstract 2654: GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma
Cancer Research·2016· 1 cited
Abstract CT022: IVAC® MUTANOME - A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma
Cancer Research·2016
Abstract CT020: MERIT: introducing individualized cancer vaccines for the treatment of TNBC - a phase I trial
Cancer Research·2016· 5 cited
High-resolution analysis of the human T-cell receptor repertoire
Nature Communications·2015· 116 citedOpen Access
Abstract CT201: The Mutanome Engineered RNA Immuno-Therapy (MERIT) project
Cancer Research·2015· 1 cited
Abstract CT202: IVAC MUTANOME: Individualized vaccines for the treatment of cancer
Cancer Research·2015· 4 cited
Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing
Current Gene Therapy·2015· 68 cited
C-8. Immunological and Metabolic Correction After Lentiviral Vector Gene Therapy for ADA Deficiency
Molecular Therapy·2015· 10 citedOpen Access
High-throughput monitoring of integration site clonality in preclinical and clinical gene therapy studies
Molecular Therapy — Methods & Clinical Development·2015· 13 citedOpen Access
Cell Cycle Status of CD34+ Hemopoietic Stem Cells Determines Lentiviral Integration in Actively Transcribed and Development-related Genes
Molecular Therapy·2014· 13 citedOpen Access
Gene Therapy for Wiskott-Aldrich Syndrome—Long-Term Efficacy and Genotoxicity
Science Translational Medicine·2014· 543 citedOpen Access
Gene therapy for Wiskott-Aldrich Syndrome—Long-term reconstitution and clinical benefits, but increased risk for leukemogenesis
Rare Diseases·2014· 28 citedOpen Access
Hematopoietic Stem Cell Gene Therapy For Wiskott- Aldrich Syndrome
Blood·2013· 4 cited
Long-Term Immunological Profile and T Cell Dynamics In Patients Treated With Allogeneic Transplantation and TK-Cells For Hematological Malignancies
Blood·2013
Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia
British Journal of Haematology·2013· 46 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Christof von Kalle(26), Manfred Schmidt(25), Hanno Glimm(17), Anne I.J. Arens(11), Uğur Şahin(8), Valesca Bukur(7), Andreas N. Kuhn(7), Claudia R. Ball(7), Cynthia C. Bartholomae(7), Annette Deichmann(7), Adrian J. Thrasher(7), Sandra Heesch(6), Jan Diekmann(6), Sebastian Kreiter(6), Christoph Klein(6), Ali Nowrouzi(6), Evelyna Derhovanessian(5), Martin Löwer(5), Kaan Boztuǧ(5), Richard Gabriel(5)